Loading stock data…
Orchestra BioMed Holdings (OBIO)
$4.75+0.51 (+12.03%)
After Hours$4.72-0.03 (-0.63%)· Last close Jun 29
Orchestra BioMed Holdings, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Orchestra BioMed Holdings, Inc. in the Healthcare sector is trading at $4.75 with a market capitalization of $238M. Wall Street consensus targets $12.17 (6 analysts), implying a +156.1% move over the next 12 months. The stock is currently 12% below its 52-week high of $5.42, remaining 18.5% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +156.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $110,000↓ | $30.92M↑ | $861,000↑ | $836,000↓ | $868,000 |
| Gross Profit | $78,000↓ | $30.87M↑ | $812,000↑ | $790,000↓ | $824,000 |
| Operating Income | -$22.08M↓ | $6.75M↑ | -$20.31M↓ | -$19.33M↓ | -$18.92M |
| Net Income | -$20.69M↓ | $6.25M↑ | -$20.83M↓ | -$19.36M↓ | -$18.75M |
Peer Comparison
JNJUNHPFE
Fundamentals
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$238.33M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-132.64%
Volume
Today's trading volume
618,934
Recent News
Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +16.98% and -94.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +0.94% and +18.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +1.12% and -57.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of -55.00% and +3.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?